EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing

Amy J Turner iD, Cyrine E Haidar iD, Wenjian Yang iD, Erin C Boone iD, Steven M Offer, Philip E Empey iD, Andrew Haddad iD, Saba Tahir, Gunter Scharer iD, Ulrich Broeckel, Andrea Gaedigk iD

Clinical and Translational Science · 2024-01 · 17 (1)

DOI: 10.1111/cts.13699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 10.01.2024. Verfasst von Amy J Turner und 10 weiteren Autor:innen. Beteiligte Einrichtung: RPRD Diagnostics LLC, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Dihydrouracil Dehydrogenase (NADP), Population Health. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The DPYD gene encodes dihydropyrimidine dehydrogenase, the rate‐limiting enzyme for the metabolism of fluoropyrimidines 5‐fluorouracil and capecitabine. Genetic variants in DPYD have been associated with altered enzyme activity, therefore accurate detection and interpretation is critical to predict metabolizer status for individualized fluoropyrimidine therapy. The most commonly observed deleterious variation is the causal variant linked to the previously described HapB3 haplotype, c.1129‐5923C>G (rs75017182) in intron 10, which introduces a cryptic splice site. A benign synonymous variant in exon 11, c.1236G>A (rs56038477) is also linked to HapB3 and is commonly used for testing. Previously, these single‐nucleotide polymorphisms (SNPs) have been reported to be in perfect linkage disequilibrium (LD); therefore, c.1236G>A is often utilized as a proxy for the function‐altering intronic variant. Clinical genotyping of DPYD identified a patient who had c.1236G>A, but not c.1129‐5923C>G, suggesting that these two SNPs may not be in perfect LD, as previously assumed. Additional individuals with c.1236G>A, but not c.1129‐5923C>G, were identified in the Children's Mercy Data Warehouse and the All of Us Research Program version 7 cohort substantiating incomplete SNP linkage. Consequently, testing only c.1236G>A can generate false‐positive results in some cases and lead to suboptimal dosing that may negatively impact patient therapy and prospect of survival. Our data show that DPYD genotyping should include the functional variant c.1129‐5923C>G, and not the c.1236G>A proxy, to accurately predict DPD activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dihydrouracil Dehydrogenase (NADP)Population HealthChildHumansHaplotypesAntimetabolites, AntineoplasticPharmacogenomic TestingGenotype

Substanzen

Dihydrouracil Dehydrogenase (NADP)Antimetabolites, Antineoplastic

Autor:innen und Institutionen

  • RPRD Diagnostics LLC, Milwaukee, Wisconsin, USA.
  • Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA.
  • Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
  • Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Amy J Turner, Cyrine E Haidar, Wenjian Yang, Erin C Boone, Philip E Empey, Andrew Haddad, Gunter Scharer, Andrea Gaedigk

Förderung

  • NIH HHS
  • NCI NIH HHS

Zitieren

APA

Turner, A. J., Haidar, C. E., Yang, W., Boone, E. C., Offer, S. M., Empey, P. E., Haddad, A., Tahir, S., Scharer, G., Broeckel, U., & Gaedigk, A. (2024). Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing. Clinical and Translational Science, 17(1). https://doi.org/10.1111/cts.13699

Vancouver

Turner AJ, Haidar CE, Yang W, Boone EC, Offer SM, Empey PE, et al. Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing. Clinical and Translational Science. 2024;17(1). doi:10.1111/cts.13699

BibTeX
@article{Turner2024,
  author = {Turner, Amy J and Haidar, Cyrine E and Yang, Wenjian and Boone, Erin C and Offer, Steven M and Empey, Philip E and Haddad, Andrew and Tahir, Saba and Scharer, Gunter and Broeckel, Ulrich and Gaedigk, Andrea},
  title = {Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing},
  journal = {Clinical and Translational Science},
  year = {2024},
  volume = {17},
  number = {1},
  doi = {10.1111/cts.13699}
}
Kostenlos starten →